Bicara Therapeutics Inc. (BCAX) Form 8-K — Jul 28, 2026

$BCAXForm 8-KItems 5.02, 7.01, 9.01Filed Jul 28, 2026, 8:35 AM ET0001628280-26-049937Original filing

Bicara Therapeutics announced board changes effective July 28, 2026, including the resignation of founding director Kiran Mazumdar-Shaw and the appointment of Jeremy Bender, Ph.D., and Christy Oliger as new independent directors to fill Class I and Class II vacancies respectively. Dr. Bender, former CEO of Day One Biopharmaceuticals, and Ms. Oliger, former Senior Vice President at Genentech, bring significant commercial and strategic experience to support Bicara's transition towards commercialization of its lead asset ficerafusp alfa.

Key figures

Board Size: 10
Stock Options Per New Director: 38950

Price after filing

1 day: -3.7%7 days: -2.9%30 days: -8.0%

Close on the filing date to close N calendar days later (from $26.88). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.